Ira Klein, MD, Discusses Quality Measures in Oncology
Ira Klein, MD, MBA, FACP, Chief Medical Officer, National Accounts Clinical Sales & Strategy, Aetna, addresses measurement programs used in oncology. Dr. Klein says that measurement is a driver for value and healthcare in the future. Quality measures like QOPI and HEDIS allow oncologists to measure how they should be rewarded and recognized for making improvement.
This video was taken on November 16 at AJMC's Translating Evidence-Based Research Into Value-Based Decisions in Oncology.
Research presented at the 56th Annual Meeting of the American Society for Radiation Oncology identified VEGF-A and TGF-beta as markers of treatment decision in patients with esophageal squamous cell carcinoma.
Rapid advances in detection technology, coupled with an increased awareness about screening, have ignited a debate on overdiagnosis and overtreatment of precancerous lesions. Should physicians use their discretion and implement a "wait-and-watch" approach?
Despite reported glitches, CMS plans to launch the database that will provide information on payments for research, gifts, meals, or speaker fees received by providers and teaching hospitals from the pharmaceutical industry.